The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey.

By N. Torrance, Blair H. Smith, M. Bennett, Amanda J Lee. Journal of Pain, 2006

976 citations recorded by the source corpus.

Subfields: Anesthesiology and Pain Medicine, Pharmacology, Physiology

View Paper: https://www.semanticscholar.org/paper/515078678b12aab8e68fa73a44466845c48e92cf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Anesthesiology and Pain Medicine

1. Clifford J. Woolf
2. R. Baron
3. Steven P. Cohen
4. T. S. Jensen
5. Blair H. Smith
6. L. Manchikanti

In Pharmacology

1. J. Scholz
2. Blair H. Smith
3. Steven P. Cohen
4. D. Turk
5. T. S. Jensen
6. N. Attal
7. R. Baron
8. Clifford J. Woolf

In Physiology

1. Clifford J. Woolf
2. T. S. Jensen
3. R. Baron
4. J. Scholz
5. Steven P. Cohen
6. M. Costigan
7. Blair H. Smith
8. N. Attal

Citations in the corpus

• Development and initial validation of an expanded and revised version of the Short‐form McGill Pain Questionnaire (SF‐MPQ‐2) (2009, background): “Although our distinction between neuropathic and non-neuropathic pain was based on current diagnostic approaches [44], its validity is further mitigated by the heterogeneity of neuropathic pain and its underlying mechanisms and the existence of chronic pain conditions— for example, low back pain—tha”
• Prevalence of chronic pain with neuropathic characteristics in the general population (2008, neutral): “(Torrance et al., 2006).”
• EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision (2010, background): “Background and objectives Neuropathic pain (NP) may be caused by a lesion or a disease of the somatosensory system [1] and is estimated to afflict as high as 7–8% of the general population in Europe [2,3].”
• Comprehensive review of epidemiology, scope, and impact of spinal pain. (2009, background): “When pain persists for weeks or months, its broader effects on well-being can be profound with significant impairment of physical and psychological health, and performance of social responsibilities including work and family (5-35).”
• Neuropathic Pain (2012, neutral): “o f lif e P D N [3 9 ,5 6 ] M ix e d [4 1 ] P D N , [5 2 ]”
• Neuropathic pain in the general population: A systematic review of epidemiological studies (2014, background): “Some studies were funded by government, charity, or nonprofit organisations [8,15,21–23,26,30,38]; others had educational grants from industry but no authorship [4,6,7,10,24,35,42]; and the remainder were conducted and/or supported by pharmaceutical industry and had declared authorship [9,13,14,18,1”
• Neuropathic Pain (2009, background): “(Bouhassira et al. 2008, Dieleman et al. 2008, Torrance et al. 2006).”
• Spinal cord stimulation versus conventional medical management for neuropathic pain: A multicentre randomised controlled trial in patients with failed back surgery syndrome (2007, background): “5–8% (Bennett, 1998; Hall et al., 2006; Torrance et al., 2006), however, neuropathic pain is often under-diagnosed and under-treated (Taylor, 2006).”
• Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). (2014, neutral): “Neuropathic pain is a major public health problem because of its prevalence (affecting up to 6–7% of the general population (Torrance et al., 2006; Bouhassira et al., 2008) and because of the limited efficacy of current therapies: only 30–40% of patients declare they receive satisfactory (>50”